Does IV Iron Induce Plasma Oxidative Stress in Critically Ill Patients? A Comparison With Healthy Volunteers*

TitreDoes IV Iron Induce Plasma Oxidative Stress in Critically Ill Patients? A Comparison With Healthy Volunteers*
Type de publicationArticle de revue
AuteurLasocki, Sigismond, Piednoir, Pascale, Couffignal, Camille, Rineau, Emmanuel , Dufour, Guillaume, Lefebvre, Thibaud, Puy, Hervé, Duval, Xavier, Driss, Fathi, Schilte, Clementine
EditeurLippincott, Williams & Wilkins
TypeArticle scientifique dans une revue à comité de lecture
Année2016
LangueAnglais
DateMars 2016
Numéro3
Pagination521-530
Volume44
Titre de la revueCritical Care Medicine
ISSN0090-3493
Résumé en anglais

Objective:

To compare the oxidative stress induced by IV iron infusion in critically ill patients and in healthy volunteers.

Design:

Multicenter, interventional study.

Setting:

Two ICUs and one clinical research center.

Subjects:

Anemic critically ill patients treated with IV iron and healthy volunteers.

Interventions:

IV infusion of 100 mg of iron sucrose.

Measurements and Main Results:

Thirty-eight anemic patients (hemoglobin, median [interquartile range] = 8.4 g/dL [7.7–9.2]) (men, 25 [66%]; aged 68 yr [48–77]; Simplified Acute Physiology Score II, 48.5 [39–59]) and 39 healthy volunteers (men, 18 [46%]; aged 42.1 yr [29–50]) were included. Blood samples were drawn before (H0) and 2, 6, and 24 hours (H2, H6, and H24) after a 60-minute iron infusion for the determination of nontransferrin bound iron, markers of lipid peroxidation—8α-isoprostanes, protein oxidation—advanced oxidized protein product, and glutathione reduced/oxidized. Iron infusion had no effect on hemodynamic parameter in patients and volunteers. At baseline, patients had much higher interleukin-6, C-reactive protein, and hepcidin levels. 8α-isoprostanes was also higher in patients at baseline (8.5 pmol/L [6.5–12.9] vs 4.6 pmol/L [3.5–5.5]), but the area under the curve above baseline from H0 to H6 was not different (p = 0.38). Neither was it for advanced oxidized protein product and nontransferrin bound iron. The area under the curve above baseline from H0 to H6 (glutathione reduced/oxidized) was lower in volunteers (p = 0.009). Eight patients had a second set of dosages (after the fourth iron infusion), showing higher increase in 8α-isoprostanes.

Conclusions:

In our observation, IV iron infusion does not induce more nontransferrin bound iron, lipid, or protein oxidation in patients compared with volunteers, despite higher inflammation, oxidative stress, and hepcidin levels and lower antioxidant at baseline. In contrary, iron induces a greater decrease in antioxidant, compatible with higher oxidative stress in volunteers than in critically ill patients.

URL de la noticehttp://okina.univ-angers.fr/publications/ua18451
DOI10.1097/CCM.0000000000001420
Lien vers le document

https://insights.ovid.com/crossref?an=00003246-201603000-00009

Titre abrégéCritical Care Medicine